Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

NCT03465059 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Insufficiency & Healthy Subjects

Interventions

DRUG: Zanubrutinib

Sponsor

BeiGene